Additional file 12: of Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas
- An-An Yin (6701297)
- Ya-Long He (6701300)
- Amandine Etcheverry (631352)
- Yu-He Liu (6701303)
- Marc Aubry (87312)
- Jill Barnholtz-Sloan (125096)
- Bo-Lin Liu (6701306)
- Jean Mosser (65312)
- Zi-Fan Lu (6701309)
- Xiang Zhang (19800)
DOIAbstract
Figure S6. The clinical performance of the RISK-score signature in combination with conventional risk factors in the setting of the combination treatment of RT and TMZ; (A) the risk classification of the RISK-score signature in combination with age (âĽ60 vs. <60 yrs; left) and MGMT promoter methylation status (right); (B) time-dependent ROC values of the RISK-score signature, age, MGMT promoter methylation status, and their combinations at each time point within all patients who underwent RT/TMZ from RAUH and TCGA-Brennan et al; (C) time-dependent ROC values of the RISK-score signature in comparison with MGMT promoter methylation status in subgroups of different ages at each time point; TCGA=The Cancer Genome Atlas; RAUH=Rennes and Angers ...
Add to ORKG